- Home
- SCLXW vs INSM Comparison
SCLXW vs INSM Comparison
Compare SCLXW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- INSM
- Stock Information
- Founded
- SCLXW N/A
- INSM 1988
- Country
- SCLXW United States
- INSM United States
- Employees
- SCLXW 113
- INSM N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- SCLXW Health Care
- INSM Health Care
- Exchange
- SCLXW Nasdaq
- INSM Nasdaq
- Market Cap
- SCLXW N/A
- INSM N/A
- IPO Year
- SCLXW 2021
- INSM 2000
- Fundamental
- Price
- SCLXW $0.24
- INSM $72.51
- Analyst Decision
- SCLXW
- INSM Strong Buy
- Analyst Count
- SCLXW 0
- INSM 16
- Target Price
- SCLXW N/A
- INSM $84.29
- AVG Volume (30 Days)
- SCLXW N/A
- INSM 2.0M
- Earning Date
- SCLXW N/A
- INSM 02-20-2025
- Dividend Yield
- SCLXW N/A
- INSM N/A
- EPS Growth
- SCLXW N/A
- INSM N/A
- EPS
- SCLXW N/A
- INSM N/A
- Revenue
- SCLXW N/A
- INSM $342,958,000.00
- Revenue This Year
- SCLXW N/A
- INSM $19.22
- Revenue Next Year
- SCLXW N/A
- INSM $41.46
- P/E Ratio
- SCLXW N/A
- INSM N/A
- Revenue Growth
- SCLXW N/A
- INSM 22.13
- 52 Week Low
- SCLXW N/A
- INSM $21.92
- 52 Week High
- SCLXW N/A
- INSM $80.53
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- INSM 57.48
- Support Level
- SCLXW N/A
- INSM $61.50
- Resistance Level
- SCLXW N/A
- INSM $70.75
- Average True Range (ATR)
- SCLXW 0.00
- INSM 2.75
- MACD
- SCLXW 0.00
- INSM 0.57
- Stochastic Oscillator
- SCLXW 0.00
- INSM 90.80
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.